Trial Profile
Phase II Correlative Study of Denosumab Effects on Tissue and Imaging Breast Biomarkers
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Feb 2022
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Breast cancer
- Focus Biomarker; Therapeutic Use
- 19 Jan 2022 Status changed from recruiting to completed.
- 18 Dec 2018 Planned End Date changed from 1 Nov 2018 to 1 Nov 2020.
- 18 Dec 2018 Planned primary completion date changed from 1 Nov 2018 to 1 Nov 2020.